Phillips-Medisize Exhibits During DDL2017

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Phillips-Medisize will exhibit at the Drug Delivery to the Lungs Conference, which is taking place at Edinburgh International Conference Center on December 6-8, 2017.
DDL is Europe’s premier conference and exhibition dedicated to pulmonary and nasal drug delivery. Treating and monitoring chronic respiratory diseases such as asthma, where patients can self-administer today with established dry powder inhalers (DPIs) and metered dose inhalers (MHIs), as well as more recent soft mist inhalers (SMIs) is another theme during DDL.
As the development partner of the first DPI, and being involved in the development of various inhaler programs, Phillips-Medisize has been at the forefront of inhalation technology for over 30 years. The company’s experience spans the entire system, from feasibility to selecting the right components – through to commercial scale production including electronics integration.
Devices for connected health solutions where respiratory devices, connected services and drugs are completely integrated are also a theme at Phillips-Medisize’s exhibition stand. Visitors can discuss how getting better therapeutic results in the respiratory field can be achieved by superior devices and improved patient engagement.
Bill Welch, Chief Technology Officer Phillips-Medisize remarked, “We continue to be very focused on partnerships built on innovation, as well as our continuum of contract services for digital interfaces to maximize the patient and caregiver experience. With the acquisition by Molex, we also vertically integrating electronics into our existing capabilities on respiratory devices.”